{"nctId":"NCT00063622","briefTitle":"Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)","startDateStruct":{"date":"2005-01"},"conditions":["Liver Diseases"],"count":247,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pioglitazone"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: Vitamin E"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching placebo"]}],"interventions":[{"name":"Pioglitazone","otherNames":["Actos"]},{"name":"Vitamin E","otherNames":["Nature Made"]},{"name":"Matching placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"* Histologic evidence of NASH based on a liver biopsy obtained within 6 months of randomization.\n* Age 18 years or older","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Improvement in Non-alcoholic Fatty Liver Disease (NAFLD) Activity Defined by Change in Standardized Scoring of Liver Biopsies at Baseline and After 96 Weeks of Treatment.","description":"Total nonalcoholic fatty liver disease (NAFLD) activity was assessed on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (assessed on a scale of 0 to 3), lobular inflammation (assessed on a scale of 0 to 3), and hepatocellular ballooning (assessed on a scale of 0 to 2). The primary outcome was an improvement in histological findings from baseline to 96 weeks, which required an improvement by 1 or more points in the hepatocellular ballooning score; no increase in the fibrosis score; and either a decrease in the activity score for nonalcoholic fatty liver disease to a score of 3 or less or a decrease in the activity score of at least 2 points, with at least a 1-point decrease in either the lobular inflammation or steatosis score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Steatosis","description":"Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score, which indicates improvement in steatosis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Lobular Inflammation","description":"Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score, which indicates improvement in lobular inflammation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Hepatocellular Ballooning","description":"Hepatocellular ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe hepatocellular ballooning. This secondary outcome measure is the number of participants that experienced a decrease in hepatocellular ballooning score, which indicates improvement in hepatocellular ballooning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Fibrosis","description":"Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score, which indicates improvement in fibrosis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Resolution of Definite Nonalcoholic Steatohepatitis","description":"The criteria for nonalcoholic steatohepatitis was definite or possible steatohepatitis (assessed by a pathologist) with an activity score of 5 or more, or definite steatohepatitis (confirmed by two pathologists) with an activity score of 4. This secondary outcome measure is the number of participants who met this definition at baseline and did not meet this definition after 96 weeks of treatment and thus had a resolution of steatohepatitis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":80},"commonTop":["Other mild and moderate adverse event","Cardiovascular Event","Bone fracture","Diabetes","Cirrhosis"]}}}